BACKGROUND: The birth of a boy is significantly more common than a girl prior to secondary recurrent miscarriage (SRM) and is associated with a poorer chance of a subsequent live birth. Children born after SRM are more likely to be girls. High-titer antisera specific for male antigens (H-Y) have been shown to arrest development of male bovine embryos efficiently. We consequently questioned the role of H-Y antibodies in women with SRM. METHODS: Serum samples from patients with unexplained SRM (n = 84), unexplained primary recurrent miscarriage (PRM) (n = 12) and healthy women (n = 37) were obtained. The samples were taken during pregnancy (gestational weeks 4-5) for 77 (80%) of the patients. Enzyme-linked immunosorbent assay was used to detect immunoglobulin G antibodies that specifically recognized any of the five recombinant H-Y proteins (EIF1AY, RPS4Y1, ZFY, DDX3Y and UTY) and their H-X homologs. RESULTS: H-Y-specific antibodies were more frequent in SRM patients (46%) compared with female controls (19%, P = 0.004) and PRM patients (8%, P = 0.01). The presence of H-Y antibodies in early pregnancy was associated with a low male: female birth ratio among the subsequent live births, as only 12% of children born to H-Y antibody-positive patients were boys compared with 44% boys born to H-Y antibody negative patients (P = 0.03). CONCLUSIONS: The high frequency of H-Y antibody-positive SRM patients and the association between the presence of these antibodies in early pregnancy and the low number of male offspring, suggest that maternal immune responses against H-Y antigens can cause pregnancy losses. Further exploring these mechanisms may increase our understanding of unexplained SRM.
BACKGROUND: The birth of a boy is significantly more common than a girl prior to secondary recurrent miscarriage (SRM) and is associated with a poorer chance of a subsequent live birth. Children born after SRM are more likely to be girls. High-titer antisera specific for male antigens (H-Y) have been shown to arrest development of male bovine embryos efficiently. We consequently questioned the role of H-Y antibodies in women with SRM. METHODS: Serum samples from patients with unexplained SRM (n = 84), unexplained primary recurrent miscarriage (PRM) (n = 12) and healthy women (n = 37) were obtained. The samples were taken during pregnancy (gestational weeks 4-5) for 77 (80%) of the patients. Enzyme-linked immunosorbent assay was used to detect immunoglobulin G antibodies that specifically recognized any of the five recombinant H-Y proteins (EIF1AY, RPS4Y1, ZFY, DDX3Y and UTY) and their H-X homologs. RESULTS: H-Y-specific antibodies were more frequent in SRM patients (46%) compared with female controls (19%, P = 0.004) and PRM patients (8%, P = 0.01). The presence of H-Y antibodies in early pregnancy was associated with a low male: female birth ratio among the subsequent live births, as only 12% of children born to H-Y antibody-positive patients were boys compared with 44% boys born to H-Y antibody negative patients (P = 0.03). CONCLUSIONS: The high frequency of H-Y antibody-positive SRM patients and the association between the presence of these antibodies in early pregnancy and the low number of male offspring, suggest that maternal immune responses against H-Y antigens can cause pregnancy losses. Further exploring these mechanisms may increase our understanding of unexplained SRM.
Authors: H S Nielsen; R Steffensen; M Lund; L Egestad; L H Mortensen; A-M N Andersen; Ø Lidegaard; O B Christiansen Journal: Hum Reprod Date: 2010-04-14 Impact factor: 6.918
Authors: C Kollman; C W Howe; C Anasetti; J H Antin; S M Davies; A H Filipovich; J Hegland; N Kamani; N A Kernan; R King; V Ratanatharathorn; D Weisdorf; D L Confer Journal: Blood Date: 2001-10-01 Impact factor: 22.113
Authors: E H Warren; M A Gavin; E Simpson; P Chandler; D C Page; C Disteche; K A Stankey; P D Greenberg; S R Riddell Journal: J Immunol Date: 2000-03-01 Impact factor: 5.422
Authors: M F P D-T Ramalho; J M Garcia; C R Esper; R Vantini; B C A Alves; I L Almeida Junior; V F M Hossepian de Lima; C A Moreira-Filho Journal: Theriogenology Date: 2004-12 Impact factor: 2.740
Authors: David B Miklos; Haesook T Kim; Emmanuel Zorn; Ephraim P Hochberg; Luxuan Guo; Alex Mattes-Ritz; Sebastien Viatte; Robert J Soiffer; Joseph H Antin; Jerome Ritz Journal: Blood Date: 2003-09-25 Impact factor: 22.113
Authors: Rob M Verdijk; Antoinette Kloosterman; Jos Pool; Maarten van de Keur; Albert M I H Naipal; Astrid G S van Halteren; Anneke Brand; Tuna Mutis; Els Goulmy Journal: Blood Date: 2003-10-30 Impact factor: 22.113
Authors: Patrick A Ott; Marcus T Dittrich; Bernhard A Herzog; Robert Guerkov; Peter A Gottlieb; Amy L Putnam; Ivana Durinovic-Bello; Bernhard O Boehm; Magdalena Tary-Lehmann; Paul V Lehmann Journal: J Clin Immunol Date: 2004-07 Impact factor: 8.317
Authors: Hideki Nakasone; Bita Sahaf; Lu Tian; Tao Wang; Michael D Haagenson; Kelsi Schoenrock; Spenser Perloff; Christine E Ryan; Fang Wu; Stephen R Spellman; Stephanie J Lee; Jerome Ritz; David B Miklos Journal: Haematologica Date: 2015-10-22 Impact factor: 9.941
Authors: Robert S Nickel; Jeanne E Hendrickson; Marianne M Yee; Robert A Bray; Howard M Gebel; Leslie S Kean; David B Miklos; John T Horan Journal: Br J Haematol Date: 2015-04-19 Impact factor: 6.998
Authors: Rachna Aggarwal; Andrea L Sestak; Eliza F Chakravarty; John B Harley; R Hal Scofield Journal: J Rheumatol Date: 2013-02-01 Impact factor: 4.666
Authors: Anders P Mikkelsen; Pia Egerup; Julie F M Ebert; Astrid M Kolte; Henriette S Nielsen; Øjvind Lidegaard Journal: EClinicalMedicine Date: 2019-10-09